NasdaqGS - Nasdaq Real Time Price
USD
Recursion Pharmaceuticals, Inc. (RXRX)
3.5200
+0.0200
(+0.57%)
At close: November 6 at 4:00:00 PM EST
3.5278
+0.0078
(+0.22%)
After hours: November 6 at 7:59:37 PM EST
Trade RXRX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreRecent transactions
Powered by Yahoo ScoutRecursion Pharmaceuticalsreported 2 insider transactionstotaling $97,222.74. Activity consisted of 1 tax paymentof $18,400.36and 1 saleof $78,822.38. Average transaction valuewas $48,611.37across the two filings.
Insider Roster
Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.
| Individual or Entity | Most Recent Transaction | Date | Shares Owned as of Transaction Date |
|---|---|---|---|
| BORGESON BLAKE CHARLES Director |
Sale | Nov 3, 2026 | 6,068,290 |
| DAR ZAVAIN Director |
Stock Award(Grant) | Jul 1, 2026 | 240,764 |
| GIBSON CHRISTOPHER C. Director |
Conversion of Exercise of derivative security | Jun 5, 2026 | 883,735 |
| HALLETT DAVID Officer |
Stock Award(Grant) | Feb 6, 2026 | 1,109,060 |
| HERSHBERG ROBERT M Director |
Conversion of Exercise of derivative security | Oct 6, 2026 | 162,156 |
| KHAN NAJAT Chief Executive Officer |
Sale | Sep 8, 2026 | 2,072,890 |
| LI DEAN Y Director |
Stock Award(Grant) | Jul 1, 2026 | 3,316,380 |
| MICHOR FRANZISKA PH.D. Director |
Stock Award(Grant) | Jun 17, 2026 | 215,477 |
| SECORA MICHAEL Chief Financial Officer |
Conversion of Exercise of derivative security | Nov 13, 2024 | 1,499,630 |
| TAYLOR BEN R Chief Financial Officer |
Sale | Mar 17, 2026 | 1,180,320 |
